Allogene Therapeutics (ALLO) Operating Leases (2018 - 2026)

Allogene Therapeutics has disclosed Operating Leases across 9 years of filings, most recently posting $81.1 million for Q1 2026.

• Operating Leases for Q1 2026 came in at $81.1 million, changed 0.3% year-over-year; the trailing twelve-month figure through Mar 2026 was $81.1 million (changed 0.3% YoY), and the FY2025 annual result was $83.3 million, down 8.27% from the prior year.
• Operating Leases came in at $81.1 million for Q1 2026 at Allogene Therapeutics, down from $83.3 million in the prior quarter.
• In the past five years, Operating Leases ranged from a high of $101.1 million in Q4 2022 to a low of $69.0 million in Q1 2022.
• The 5-year median for Operating Leases is $88.3 million (2023), against an average of $87.2 million.
• Across the five-year window, Operating Leases jumped 90.97% in 2022 and retreated 12.64% in 2023, its largest moves.
• Allogene Therapeutics' Operating Leases stood at $101.1 million in 2022, then retreated by 12.64% to $88.3 million in 2023, then advanced by 2.73% to $90.8 million in 2024, then dropped by 8.27% to $83.3 million in 2025, then dropped by 2.64% to $81.1 million in 2026.
• The last three Operating Leases figures came in at $81.1 million (Q1 2026), $83.3 million (Q4 2025), and $77.1 million (Q3 2025), per Business Quant data.